670 related articles for article (PubMed ID: 31533922)
21. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
22. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.
Rittberg R; Czaykowski P; Niraula S
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254
[TBL] [Abstract][Full Text] [Related]
24. Association of trial registration with the results and conclusions of published trials of new oncology drugs.
Rasmussen N; Lee K; Bero L
Trials; 2009 Dec; 10():116. PubMed ID: 20015404
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
Morant AV; Jagalski V; Vestergaard HT
Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
[TBL] [Abstract][Full Text] [Related]
26. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
28. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
29. Surgery for epilepsy.
West S; Nolan SJ; Cotton J; Gandhi S; Weston J; Sudan A; Ramirez R; Newton R
Cochrane Database Syst Rev; 2015 Jul; (7):CD010541. PubMed ID: 26130264
[TBL] [Abstract][Full Text] [Related]
30. The characteristics and regulations of adaptive designs from 2008 to 2020: An overview of European Medicines Agency approvals.
Huang X; Ma J; Lu Z; Huang L
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):445-454. PubMed ID: 37548455
[TBL] [Abstract][Full Text] [Related]
31. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
Apolone G; Joppi R; Bertele' V; Garattini S
Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
[TBL] [Abstract][Full Text] [Related]
32. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
[TBL] [Abstract][Full Text] [Related]
33. Surgery for epilepsy.
West S; Nevitt SJ; Cotton J; Gandhi S; Weston J; Sudan A; Ramirez R; Newton R
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD010541. PubMed ID: 31237346
[TBL] [Abstract][Full Text] [Related]
34. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
35. Drug interventions for the treatment of obesity in children and adolescents.
Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
[TBL] [Abstract][Full Text] [Related]
36. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Naci H; Zhang Y; Woloshin S; Guan X; Xu Z; Wagner AK
Lancet Oncol; 2024 Jun; 25(6):760-769. PubMed ID: 38754451
[TBL] [Abstract][Full Text] [Related]
37. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
Awan FA; Becker AB; Wang Y; Kimmelman J
Ann Intern Med; 2022 Dec; 175(12):1675-1684. PubMed ID: 36410007
[TBL] [Abstract][Full Text] [Related]
38. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
[TBL] [Abstract][Full Text] [Related]
39. Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021.
Li J; Wang H; Hua Y; Liu Y; Chen Y; Jiang R; Shao R; Xie J
Clin Ther; 2023 Nov; 45(11):1111-1118. PubMed ID: 37806812
[TBL] [Abstract][Full Text] [Related]
40. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
Erhel F; Scanff A; Naudet F
Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
